A new study evaluated the impact of levodopa–carbidopa intestinal gel infusion (LCIG) on 56 PD patients and genetic mutations were confirmed upon genetic testing in 9/56 (15%) (5 GBA1, 2 Alpha-synuclein (SNCA), 1 LRRK2, 1 PRKN). This evidence concerns the gene GBA1 and Parkinson disease.